Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

OBJECTIVES: Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation. METHODS: A total of 110 patients eligible to receive adalimumab 40 mg subcutaneously...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducourau, Emilie, Rispens, Theo, Samain, Marine, Dernis, Emmanuelle, Le Guilchard, Fabienne, Andras, Lucia, Perdriger, Aleth, Lespessailles, Eric, Martin, Antoine, Cormier, Grégoire, Armingeat, Thomas, Devauchelle-Pensec, Valérie, Gervais, Elisabeth, Le Goff, Benoit, de Vries, Annick, Piver, Eric, Paintaud, Gilles, Desvignes, Céline, Ternant, David, Watier, Hervé, Goupille, Philippe, Mulleman, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046954/
https://www.ncbi.nlm.nih.gov/pubmed/31958280
http://dx.doi.org/10.1136/rmdopen-2019-001047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046954/
https://www.ncbi.nlm.nih.gov/pubmed/31958280
http://dx.doi.org/10.1136/rmdopen-2019-001047

Ejemplares similares